Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CT-859
- Development stage
- Preclinical
- Lead developer
- Roche
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
CT-859 is a unimolecular, fully cAMP-biased dual glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) agonist. Developed initially by Carmot Therapeutics (subsequently acquired by Roche), CT-859 is engineered to selectively stimulate cAMP signaling without recruiting beta-arrestin-1 or beta-arrestin-2, thereby preventing receptor internalization and desensitization. It serves as a mouse analogue of CT-868 and has demonstrated prolonged food intake suppression, glycemic control, and weight loss in preclinical rodent models of obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH).
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on CT-859.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CT-859.